Velázquez-Campoy A - Search Results

1

Protease inhibition in African subtypes of HIV-1.

Velázquez-Campoy A, Vega S, Fleming E, Bacha U, Sayed Y, Dirr HW, Freire E. Velázquez-Campoy A, et al. AIDS Rev. 2003 Jul-Sep;5(3):165-71. AIDS Rev. 2003. PMID: 14598565 Review.

2

HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity.

Velazquez-Campoy A, Todd MJ, Freire E. Velazquez-Campoy A, et al. Biochemistry. 2000 Mar 7;39(9):2201-7. doi: 10.1021/bi992399d. Biochemistry. 2000. PMID: 10694385

3

Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.

Todd MJ, Luque I, Velázquez-Campoy A, Freire E. Todd MJ, et al. Biochemistry. 2000 Oct 3;39(39):11876-83. doi: 10.1021/bi001013s. Biochemistry. 2000. PMID: 11009599

4

Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor.

Velazquez-Campoy A, Luque I, Todd MJ, Milutinovich M, Kiso Y, Freire E. Velazquez-Campoy A, et al. Protein Sci. 2000 Sep;9(9):1801-9. doi: 10.1110/ps.9.9.1801. Protein Sci. 2000. PMID: 11045625 Free PMC article.

5

Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Velazquez-Campoy A, et al. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7. doi: 10.1073/pnas.111152698. Epub 2001 May 15. Proc Natl Acad Sci U S A. 2001. PMID: 11353856 Free PMC article.

6

The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.

Velazquez-Campoy A, Kiso Y, Freire E. Velazquez-Campoy A, et al. Arch Biochem Biophys. 2001 Jun 15;390(2):169-75. doi: 10.1006/abbi.2001.2333. Arch Biochem Biophys. 2001. PMID: 11396919

7

Incorporating target heterogeneity in drug design.

Velazquez-Campoy A, Freire E. Velazquez-Campoy A, et al. J Cell Biochem Suppl. 2001;Suppl 37:82-8. doi: 10.1002/jcb.10068. J Cell Biochem Suppl. 2001. PMID: 11842432 Review.

8

Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.

Velazquez-Campoy A, Vega S, Freire E. Velazquez-Campoy A, et al. Biochemistry. 2002 Jul 9;41(27):8613-9. doi: 10.1021/bi020160i. Biochemistry. 2002. PMID: 12093278

9

Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

Ohtaka H, Velázquez-Campoy A, Xie D, Freire E. Ohtaka H, et al. Protein Sci. 2002 Aug;11(8):1908-16. doi: 10.1110/ps.0206402. Protein Sci. 2002. PMID: 12142445 Free PMC article.

10

Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.

Velazquez-Campoy A, Muzammil S, Ohtaka H, Schön A, Vega S, Freire E. Velazquez-Campoy A, et al. Curr Drug Targets Infect Disord. 2003 Dec;3(4):311-28. doi: 10.2174/1568005033481051. Curr Drug Targets Infect Disord. 2003. PMID: 14754432 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page